Overview

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Status:
RECRUITING

Trial end date:
2027-12-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Alterome Therapeutics, Inc.